Back to Search Results
Image Place holder

Christine Chung, MD

Chair, Department of Head and Neck-Endocrine Oncology

★★★★★
★★★★★
4.8 (58 ratings)
Specialty: Medical Oncology
Program: Head and Neck Oncology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Adrenal Carcinoma, Esophageal Cancer, Head and Neck Cancer, Neuroendocrine Tumor, Oral Cavity or Throat Cancer, Sarcoma, Skin Cancer (Nonmelanoma), Throat Cancer, Thyroid Cancer

Dr. Chung's laboratory was among the first to recognize the importance of human papillomavirus (HPV) in the etiology of certain HNC as seen in one of the four subtypes in our molecular characterization study. Specifically the research showed that the most significantly deregulated genes in the HPV-positive tumors are cell cycle regulators. These data provided evidence that HPV-positive tumors may be more sensitive to chemotherapy and molecular inhibitors that specifically target cell cycle. In addition, her research findings contributed to establish the prognostic implication of the HPV status. Patients with HPV-positive HNC have a better prognosis compared to patients with HPV-negative HNC. This work is important clinically because HPV-related HNC may not require the same level of intense, highly toxic therapy commonly employed in the management of HPV-negative HNC. In fact, in this group of patients with a good prognosis, the risk of long term toxicities may outweigh the benefit of aggressive treatment. Dr. Chung is conducting clinical trials to develop less toxic but effective molecularly targeted agents which can potentially benefit this subset of HNC patients.


Education & Training

Fellowship:

  • University of North Carolina, Chapel Hill - Medical Oncology

Residency:

  • University of North Carolina, Chapel Hill - Internal Medicine Residency

Medical School:

  • Eastern Virginia Medical School - MD
Awards
Start Year: End Year: 2017 Spirit of Moffitt Award: Head and Neck Multidisciplinary Clinic, Sponsor: Moffitt Cancer Center
Video Profile
Participating Trials

CLINICAL TRIAL 20144
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Condition: Head & Neck
Intervention: CUE-101 (); Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 21116
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Condition: Head & Neck
Intervention: Birinapant (); IMRT ()
Open

CLINICAL TRIAL 21657
Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Condition: Head & Neck
Intervention: Aloxi (Palonosetron); Aprepitant (); Dexamethasone (); Fosaprepitant (); Granisetron (); KCL (); Mannitol (); MgSO4 (); Olanzapine (); Ondansetron (); Palonosetron (); Zofran (Ondansetron); cisplatin ()
Open

CLINICAL TRIAL 21641
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGF_ Fusion Protein BCA101 Alone and in Combination with Pembrolizumab in Patients With EGFR-Driven Advanced Solid Tumors
Condition: Head & Neck
Intervention: BCA101 (); Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 21940
M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention
Condition: Head & Neck
Intervention: Metformin/Placebo ()
Open

CLINICAL TRIAL 21077
A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Condition: Head & Neck
Intervention: 5-fluorouracil (); ALX148 (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); carboplatin (); cisplatin ()
Open

CLINICAL TRIAL 21078
A Phase 2 Study of ALX148 in Combination with Pembrolizumab and chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Condition: Head & Neck
Intervention: 5-fluorouracil (); ALX148 (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); carboplatin (); cisplatin ()
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Agosto Salgado S, Kaye ER, Sargi Z, Chung CH, Papaleontiou M. Management of Advanced Thyroid Cancer: Overview, Advances, and Opportunities. Am Soc Clin Oncol Educ Book. 2023 May.43:e389708. Pubmedid: 37186883.
  • Subramaniam RM, DeMora L, Yao M, Yom SS, Gillison M, Caudell JJ, Waldron J, Xia P, Chung C, Truong MT, Echevarria M, Chan JW, Geiger JL, Mell L, Seaward S, Thorstad WL, Beitler JJ, Sultanem K, Blakaj D, Le QT. 18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus-Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002. J Nucl Med. 2023 Mar.64(3):362-367. Pubmedid: 36215572. Pmcid: PMC10071810.
  • Lin CN, Chung CH, Tan AC. NuKit: A deep learning platform for fast nucleus segmentation of histopathological images. J Bioinform Comput Biol. 2023 Mar.2350002. Pubmedid: 36958934.
  • Bauman JE, Saba NF, Roe D, Bauman JR, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Klein R, Saboda K, Obara S, Chung CH. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. J Clin Oncol. 2023 Mar.JCO2201994. Pubmedid: 36977289.
  • Sherman EJ, Harris J, Bible KC, Xia P, Ghossein RA, Chung CH, Riaz N, Gunn GB, Foote RL, Yom SS, Wong SJ, Koyfman SA, Dzeda MF, Clump DA, Khan SA, Shah MH, Redmond K, Torres-Saavedra PA, Le QT, Lee NY. Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial. Lancet Oncol. 2023 Feb.24(2):175-186. Pubmedid: 36681089. Pmcid: PMC9969528.
  • Cao B, Patel KB, Li T, Yao S, Chung CH, Wang X. A subnetwork-based framework for prioritizing and evaluating prognostic gene modules from cancer transcriptome data. iScience. 2023 Feb.26(2):105915. Pubmedid: 36685033. Pmcid: PMC9845797.
  • Patel KB, Padhya TA, Huang J, Hernandez-Prera JC, Li T, Chung CH, Wang L, Wang X. Plasma cell-free DNA methylome profiling in pre- and post-surgery oral cavity squamous cell carcinoma. Mol Carcinogen. 2023 Apr.62(4):493-502. Pubmedid: 36636912. Pmcid: PMC10023468.
  • Saba NF, Steuer CE, Ekpenyong A, McCook-Veal A, Magliocca K, Patel M, Schmitt NC, Stokes W, Bates JE, Rudra S, Remick J, McDonald M, Abousaud M, Tan AC, Fadlullah MZH, Chaudhary R, Muzaffar J, Kirtane K, Liu Y, Chen GZ, Shin DM, Teng Y, Chung CH. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. Nat Med. 2023 Apr.29(4):880-887. Pubmedid: 37012550. Pmcid: PMC10205145.
  • Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, Schenker M, Bratland Å, Walker JWT, Grell P, Even C, Chung CH, Redman R, Coutte A, Salas S, Grant C, de Azevedo S, Soulières D, Hansen AR, Wei L, Khan TA, Miller-Moslin K, Roberts M, Haddad R. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial. JAMA Oncol. 2023 Apr. Pubmedid: 37022706. Pmcid: PMC10080406.
  • Echevarria MI, Yang GQ, Chen DT, Kirtane K, Russell J, Kish J, Muzaffar J, Otto K, Padhya T, McMullen C, Patel K, Chung CH, Caudell JJ. Phase I dose escalation of stereotactic body radiation therapy and concurrent cisplatin for re-irradiation of unresectable, recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2023 Apr. Pubmedid: 37105404.
  • Oswald LB, Arredondo B, Geiss C, Vigoureux TFD, Hoogland AI, Chung CH, Muzaffar J, Patel KB, Gonzalez BD, Jim HSL, Kirtane K. Considerations for developing supportive care interventions for survivors of head and neck cancer: A qualitative study. Psychooncology. 2022 Sep.31(9):1519-1526. Pubmedid: 35726386. Pmcid: PMC9452460.
  • Cárdenas SD, Reznik CJ, Ranaweera R, Song F, Chung CH, Fertig EJ, Gevertz JL. Model-informed experimental design recommendations for distinguishing intrinsic and acquired targeted therapeutic resistance in head and neck cancer. NPJ Syst Biol Appl. 2022 Sep.8(1):32. Pubmedid: 36075912. Pmcid: PMC9458753.
  • Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet. 2022 Sep.400(10357):1008-1019. Pubmedid: 36108657. Pmcid: PMC9533323.
  • Dickey BL, Nedjai B, Preece MD, Schell MJ, Boulware D, Whiting J, Sirak B, Abrahamsen M, Isaacs-Soriano KA, Kennedy K, Chung CH, Giuliano AR. Methylation of HPV16 and EPB41L3 in oral gargles and the detection of early and late oropharyngeal cancer. Cancer Med. 2022 Oct.11(20):3735-3742. Pubmedid: 35619332. Pmcid: PMC9582688.
  • Kirtane K, Geiss C, Arredondo B, Hoogland AI, Chung CH, Muzaffar J, Patel KB, Gonzalez BD, Jim HSL, Oswald LB. "I have cancer during COVID; that's a special category": a qualitative study of head and neck cancer patient and provider experiences during the COVID-19 pandemic. Support Care Cancer. 2022 May.30(5):4337-4344. Pubmedid: 35091844. Pmcid: PMC8799415.
  • Oswald LB, Brownstein NC, Whiting J, Hoogland AI, Saravia S, Kirtane K, Chung CH, Vinci C, Gonzalez BD, Johnstone PAS, Jim HSL. Smoking Is Related to Worse Cancer-related Symptom Burden. Oncologist. 2022 Mar.27(2):e176-e184. Pubmedid: 35641215. Pmcid: PMC8895733.
  • Chung CH, Li J, Steuer CE, Bhateja P, Johnson M, Masannat J, Poole MI, Song F, Hernandez-Prera JC, Molina H, Wenig BM, Kumar S, Kuperwasser C, Stephens PJ, Farinhas JM, Shin DM, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF, Bonomi M. Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 Jun.28(11):2329-2338. Pubmedid: 35344035. Pmcid: PMC9167762.
  • Wang X, Muzaffar J, Kirtane K, Song F, Johnson M, Schell MJ, Li J, Yoder SJ, Conejo-Garcia JR, Guevara-Patino JA, Bonomi M, Bhateja P, Rocco JW, Steuer CE, Saba NF, Chung CH. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022 Jun.10(6). Pubmedid: 35676062. Pmcid: PMC9185557.
  • Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol. 2022 Jan.40(2):138-149. Pubmedid: 34699271. Pmcid: PMC8718241.
  • Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. J Natl Cancer Inst. 2022 Dec.114(12):1619-1627. Pubmedid: 36053203. Pmcid: PMC9745425.
  • Glazar DJ, Johnson M, Farinhas J, Steuer CE, Saba NF, Bonomi M, Chung CH, Enderling H. Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab. Oral Oncol. 2022 Apr.127:105787. Pubmedid: 35248922.
  • de la Iglesia JV, Slebos RJC, Martin-Gomez L, Wang X, Teer JK, Tan AC, Gerke TA, Aden-Buie G, van Veen T, Masannat J, Chaudhary R, Song F, Fournier M, Siegel EM, Schabath MB, Wadsworth JT, Caudell J, Harrison L, Wenig BM, Conejo-Garcia J, Hernandez-Prera JC, Chung CH. Correction: Effects of Tobacco Smoking On the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2021 Sep.27(17):4941. Pubmedid: 34470812.
  • Lee K, Lockhart JH, Xie M, Chaudhary R, Slebos RJC, Flores ER, Chung CH, Tan AC. Deep Learning of Histopathology Images at the Single Cell Level. Front Artif Intell. 2021 Sep.4:754641. Pubmedid: 34568816. Pmcid: PMC8461055.
  • Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison ML, Xia P, Truong MT, Kong C, Jordan R, Subramaniam RM, Yao M, Chung CH, Geiger JL, Chan JW, O'Sullivan B, Blakaj DM, Mell LK, Thorstad WL, Jones CU, Banerjee RN, Lominska C, Le QT. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). J Clin Oncol. 2021 Mar.39(9):956-965. Pubmedid: 33507809. Pmcid: PMC8078254.
  • Chung CH, Bonomi M, Steuer CE, Li J, Bhateja P, Johnson M, Masannat J, Song F, Hernandez-Prera JC, Wenig BM, Molina H, Farinhas JM, McMullen CP, Wadsworth JT, Patel KB, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF. Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. Cancers (Basel). 2021 Mar.13(5). Pubmedid: 33803335. Pmcid: PMC7967147.
  • Kelly RJ, Ansari AM, Miyashita T, Zahurak M, Lay F, Ahmed AK, Born LJ, Pezhouh MK, Salimian KJ, Ng C, Matsangos AE, Stricker-Krongrad AH, Mukaisho KI, Marti GP, Chung CH, Canto MI, Rudek MA, Meltzer SJ, Harmon JW. Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrett's Esophagus to Invasive Esophageal Adenocarcinoma. Ann Surg. 2021 Jun.273(6):e206-e213. Pubmedid: 31290765. Pmcid: PMC8147663.
  • Ferris RL, Spanos WC, Leidner R, Gonçalves A, Martens UM, Kyi C, Sharfman W, Chung CH, Devriese LA, Gauthier H, Chiosea SI, Vujanovic L, Taube JM, Stein JE, Li J, Li B, Chen T, Barrows A, Topalian SL. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer. 2021 Jun.9(6). Pubmedid: 34083421. Pmcid: PMC8183204.
  • Dickey BL, Sirak B, Martin-Gomez L, Reich RR, Abrahamsen M, Isaacs-Soriano K, Chung CH, Giuliano AR. Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome. PLoS One. 2021 Jul.16(7):e0254161. Pubmedid: 34214131. Pmcid: PMC8253433.
  • Kirtane K, Elmariah H, Chung CH, Abate-Daga D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J Immunother Cancer. 2021 Jul.9(7). Pubmedid: 34301811. Pmcid: PMC8311333.
  • Hernandez-Prera J, Valderrabano P, Creed J, de la Iglesia JV, Slebos R, Centeno BA, Tarasova V, Hallanger-Johnson J, Veloski C, Otto KJ, Wenig BM, Yoder S, Lam C, Park DS, Anderson AR, Raghunand N, Berglund A, Caudell J, Gerke TA, Chung CH. Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations. Thyroid. 2021 Jan.31(1):36-49. Pubmedid: 32689909. Pmcid: PMC7864115.
  • Muzaffar J, Bari S, Kirtane K, Chung CH. Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2021 Jan.13(2). Pubmedid: 33477635. Pmcid: PMC7831487.
  • Chaudhary R, Slebos RJC, Song F, McCleary-Sharpe KP, Masannat J, Tan AC, Wang X, Amaladas N, Wu W, Hall GE, Conejo-Garcia JR, Hernandez-Prera JC, Chung CH. Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. Mol Carcinogen. 2021 Feb.60(2):138-150. Pubmedid: 33378592. Pmcid: PMC7856233.
  • Hathaway CA, Siegel EM, Chung CH, Pabbathi S, Vidrine J, Vadaparampil S, Tworoger SS. Utilizing a large-scale biobanking registry to assess patient priorities and preferences for cancer research and education. PLoS One. 2021 Feb.16(2):e0246686. Pubmedid: 33544776. Pmcid: PMC7864448.
  • Shi LL, McMullen C, Vorwald K, Nichols AC, MacNeil SD, Wadsworth JT, Chung CH, Wang X, Patel KB. Survival outcomes of patients with subglottic squamous cell carcinoma : a study of the National Cancer Database. Eur Arch Otorhinolaryngol. 2021 Dec.278(12):4923-4932. Pubmedid: 33646344.
  • Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021 Aug.5(1):74. Pubmedid: 34354225. Pmcid: PMC8342450.
  • Xie M, Lee K, Lockhart JH, Cukras SD, Carvajal R, Beg AA, Flores ER, Teng M, Chung CH, Tan AC. TIMEx: tumor-immune microenvironment deconvolution web-portal for bulk transcriptomics using pan-cancer scRNA-seq signatures. Bioinformatics. 2021 Apr. Pubmedid: 33901274.
  • Sandulache VC, Lei YL, Heasley LE, Chang M, Amos CI, Sturgis EM, Graboyes E, Chiao EY, Rogus-Pulia N, Lewis J, Madabhushi A, Frederick MJ, Sabichi A, Ittmann M, Yarbrough WG, Chung CH, Ferrarotto R, Mai W, Skinner HD, Duvvuri U, Gerngross P, Sikora AG. Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting. Oral Oncol. 2020 Mar.102:104440. Pubmedid: 31648864. Pmcid: PMC7260859.
  • de la Iglesia JV, Slebos RJ, Martin-Gomez L, Wang X, Teer JK, Tan AC, Gerke TA, Aden-Buie G, Van Veen T, Masannat J, Chaudhary R, Song F, Fournier M, Siegel EM, Schabath MB, Wadsworth JT, Caudell JJ, Harrison LB, Wenig B, Conejo-Garcia JR, Hernandez-Prera JC, Chung CH. Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2020 Mar.26(6):1474-1485. Pubmedid: 31848186. Pmcid: PMC7073297.
  • Gatenbee CD, Minor ES, Slebos RJC, Chung CH, Anderson ARA. Histoecology: Applying Ecological Principles and Approaches to Describe and Predict Tumor Ecosystem Dynamics Across Space and Time. Cancer Control. 2020 Jul.27(3). Pubmedid: 32869651. Pmcid: PMC7710396.
  • Giuliano AR, Nedjai B, Lorincz AT, Schell MJ, Rahman S, Banwait R, Boulware D, Sirak B, Martin-Gomez L, Abrahamsen M, Isaacs-Soriano KA, Wenig B, Chung CH, Caudell J. Methylation of HPV 16 and EPB41L3 in oral gargles: Associations with oropharyngeal cancer detection and tumor characteristics. Int J Cancer. 2020 Feb.146(4):1018-1030. Pubmedid: 31304592. Pmcid: PMC7787351.
  • Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb.21(2):261-270. Pubmedid: 31838015. Pmcid: PMC7811790.
  • Chaudhary R, Wang X, Cao B, De La Iglesia J, Masannat J, Song F, Hernandez-Prera JC, Gimbrone NT, Slebos RJ, Chung CH. Long noncoding RNA, LINC00460, as a prognostic biomarker in head and neck squamous cell carcinoma (HNSCC). Am J Transl Res. 2020 Feb.12(2):684-696. Pubmedid: 32194915. Pmcid: PMC7061833.
  • Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebbé C, Delord JP, Dunn LA, Shinohara MM, Kulikauskas R, Chung CH, Martens UM, Ferris RL, Stein JE, Engle EL, Devriese LA, Lao CD, Gu J, Li B, Chen T, Barrows A, Horvath A, Taube JM, Nghiem P. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. J Clin Oncol. 2020 Aug.38(22):2476-2487. Pubmedid: 32324435. Pmcid: PMC7392746.
  • Lam CA, McGettigan MJ, Thompson ZJ, Khazai L, Chung CH, Centeno BA, McIver B, Valderrabano P. Ultrasound characterization for thyroid nodules with indeterminate cytology: inter-observer agreement and impact of combining pattern-based and scoring-based classifications in risk stratification. Endocrine. 2019 Nov.66(2):278-287. Pubmedid: 31300961. Pmcid: PMC7771547.
  • Martin-Gomez L, Giuliano AR, Fulp WJ, Caudell J, Echevarria M, Sirak B, Abrahamsen M, Isaacs-Soriano KA, Hernandez-Prera JC, Wenig BM, Vorwald K, McMullen CP, Wadsworth JT, Slebos RJ, Chung CH. Human Papillomavirus Genotype Detection in Oral Gargle Samples Among Men With Newly Diagnosed Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg. 2019 May.145(5):460-466. Pubmedid: 30920604. Pmcid: PMC6537790.
  • Martin-Gomez L, Fulp WJ, Schell MJ, Sirak B, Abrahamsen M, Isaacs-Soriano KA, Lorincz A, Wenig B, Chung CH, Caudell JJ, Giuliano AR. Oral gargle-tumor biopsy human papillomavirus (HPV) agreement and associated factors among oropharyngeal squamous cell carcinoma (OPSCC) cases. Oral Oncol. 2019 May.92:85-91. Pubmedid: 31010629. Pmcid: PMC6736648.
  • Li Q, Yu X, Chaudhary R, Slebos RJC, Chung CH, Wang X. lncDIFF: a novel quasi-likelihood method for differential expression analysis of non-coding RNA. BMC Genomics. 2019 Jul.20(1):539. Pubmedid: 31266446. Pmcid: PMC6604377.
  • Yu X, Chen YA, Conejo-Garcia JR, Chung CH, Wang X. Estimation of immune cell content in tumor using single-cell RNA-seq reference data. BMC Cancer. 2019 Jul.19(1):715. Pubmedid: 31324168. Pmcid: PMC6642583.
  • McMullen C, Chung CH, Hernandez-Prera JC. Evolving role of human papillomavirus as a clinically significant biomarker in head and neck squamous cell carcinoma. Expert Rev Mol Diagn. 2019 Jan.19(1):63-70. Pubmedid: 30575409.
  • Cohen EEW, Pishvaian MJ, Shepard DR, Wang D, Weiss J, Johnson ML, Chung CH, Chen Y, Huang B, Davis CB, Toffalorio F, Thall A, Powell SF. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. J Immunother Cancer. 2019 Dec.7(1):342. Pubmedid: 31801624. Pmcid: PMC6894203.
  • Eze N, Lee JW, Yang DH, Zhu F, Neumeister V, Sandoval-Schaefer T, Mehra R, Ridge JA, Forastiere A, Chung CH, Burtness B. PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma. Oral Oncol. 2019 Apr.91:69-78. Pubmedid: 30926065. Pmcid: PMC6855599.
  • Sherman TD, Kagohara LT, Cao R, Cheng R, Satriano M, Considine M, Krigsfeld G, Ranaweera R, Tang Y, Jablonski SA, Stein-O'Brien G, Gaykalova DA, Weiner LM, Chung CH, Fertig EJ. CancerInSilico: An R/Bioconductor package for combining mathematical and statistical modeling to simulate time course bulk and single cell gene expression data in cancer. PLoS Comput Biol. 2019 Apr.14(4):e1006935. Pubmedid: 31002670. Pmcid: PMC6504085.
  • Valderrabano P, Khazai L, Thompson ZJ, Otto KJ, Hallanger-Johnson JE, Chung CH, Centeno BA, McIver B. Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid Nodules. JAMA Otolaryngol Head Neck Surg. 2018 Sep.144(9):788-795. Pubmedid: 30027226. Pmcid: PMC6233620.
  • Naghavi AO, Echevarria MI, Strom TJ, Abuodeh YA, Venkat PS, Ahmed KA, Demetriou S, Frakes JM, Kim Y, Kish JA, Russell JS, Otto KJ, Chung CH, Harrison LB, Trotti A, Caudell JJ. Patient choice for high-volume center radiation impacts head and neck cancer outcome. Cancer Med. 2018 Oct.7(10):4964-4979. Pubmedid: 30175512. Pmcid: PMC6198196.
  • Saba NF, Li S, Hussain ZA, Subramanian R, Califano JA, Chung CH. Locally advanced high-risk HPV related oropharyngeal squamous cell carcinoma (OPSCC); have we forgotten it is a different disease?. Cancers Head Neck. 2018 Oct.3:8. Pubmedid: 31093361. Pmcid: PMC6460663.
  • Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018 May.36(14):1412-1418. Pubmedid: 29584545. Pmcid: PMC5941615.
  • Stein-O'Brien G, Kagohara LT, Li S, Thakar M, Ranaweera R, Ozawa H, Cheng H, Considine M, Schmitz S, Favorov AV, Danilova LV, Califano JA, Izumchenko E, Gaykalova DA, Chung CH, Fertig EJ. Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance. Genome Med. 2018 May.10(1):37. Pubmedid: 29792227. Pmcid: PMC5966898.
  • Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul.379(4):341-351. Pubmedid: 29863979.
  • Rettig EM, Bishop JA, Agrawal N, Chung CH, Sharma R, Zamuner F, Li RJ, Koch WM, Califano JA, Guo T, Gaykalova DA, Fakhry C. HEY1 is expressed independent of NOTCH1 and is associated with poor prognosis in head and neck squamous cell carcinoma. Oral Oncol. 2018 Jul.82:168-175. Pubmedid: 29909892.
  • Bakhoum SF, Ngo B, Laughney AM, Cavallo JA, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBK, Taunk NK, Duran M, Pauli C, Shaw C, Chadalavada K, Rajasekhar VK, Genovese G, Venkatesan S, Birkbak NJ, McGranahan N, Lundquist M, LaPlant Q, Healey JH, Elemento O, Chung CH, Lee NY, Imielenski M, Nanjangud G, Pe'er D, Cleveland DW, Powell SN, Lammerding J, Swanton C, Cantley LC. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018 Jan.553(7689):467-472. Pubmedid: 29342134. Pmcid: PMC5785464.
  • Valderrabano P, Khazai L, Thompson ZJ, Sharpe SC, Tarasova VD, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Wenig BM, Chung CH, Centeno BA, McIver B. Cancer Risk Associated with Nuclear Atypia in Cytologically Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis. Thyroid. 2018 Feb.28(2):210-219. Pubmedid: 29160163. Pmcid: PMC7869885.
  • Valderrabano P, Khazai L, Thompson ZJ, Leon ME, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Chung CH, Centeno BA, McIver B. Impact of oncogene panel results on surgical management of cytologically indeterminate thyroid nodules. Head Neck. 2018 Aug.40(8):1812-1823. Pubmedid: 29624786. Pmcid: PMC7771319.
  • Valderrabano P, McGettigan MJ, Lam C, Khazai L, Thompson ZJ, Chung CH, Centeno BA, McIver B. Thyroid Nodules with Indeterminate Cytology: Utility of the American Thyroid Association Sonographic Patterns for Cancer Risk Stratification. Thyroid. 2018 Aug.28(8):1004-1012. Pubmedid: 29848195. Pmcid: PMC6916126.
  • Ozawa H, Ranaweera R, Izumchenko E, Makarev E, Zhavoronkov A, Fertig EJ, Howard JD, Markovic A, Bedi A, Ravi R, Perez J, Le QT, Kong CS, Jordan RCK, Wang H, Kang H, Quon H, Sidransky D, Chung CH. SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. Clin Cancer Res. 2017 Sep.23(17):5162-5175. Pubmedid: 28522603. Pmcid: PMC6078415.
  • Valderrabano P, Khazai L, Thompson ZJ, Leon ME, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Wenig BM, Chung CH, Centeno BA, McIver B. Cancer Risk Stratification of Indeterminate Thyroid Nodules: A Cytological Approach. Thyroid. 2017 Oct.27(10):1277-1284. Pubmedid: 28806881. Pmcid: PMC6112164.
  • Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z, Singh B, Franklin JL, Wang J, Hu H, Wei T, Yang M, Yeatman TJ, Lee E, Saito-Diaz K, Hinger S, Patton JG, Chung CH, Emmrich S, Klusmann JH, Fan D, Coffey RJ. lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat Med. 2017 Nov.23(11):1331-1341. Pubmedid: 29035371. Pmcid: PMC5961502.
  • Valderrabano P, Khazai L, Leon ME, Thompson ZJ, Ma Z, Chung CH, Hallanger-Johnson JE, Otto KJ, Rogers KD, Centeno B, McIver B. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology. Endocr Relat Cancer. 2017 Mar.24(3):127-136. Pubmedid: 28104680. Pmcid: PMC7771306.
  • Chung CH, Germain A, Subramaniam RM, Heilmann AM, Fedorchak K, Ali SM, Miller VA, Palermo RA, Fakhry C. Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma. Head Neck. 2017 Jan.39(1):E15-E19. Pubmedid: 27653501.
  • Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2017 Feb.35(5):490-497. Pubmedid: 28029303. Pmcid: PMC5455313.
  • Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017 Apr.3(4):483-491. Pubmedid: 28006059. Pmcid: PMC5470422.
  • Fertig EJ, Ozawa H, Thakar M, Howard JD, Kagohara LT, Krigsfeld G, Ranaweera RS, Hughes RM, Perez J, Jones S, Favorov AV, Carey J, Stein-O'Brien G, Gaykalova DA, Ochs MF, Chung CH. CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network. Oncotarget. 2016 Nov.7(45):73845-73864. Pubmedid: 27650546. Pmcid: PMC5342018.
  • Cheng H, Fertig EJ, Ozawa H, Hatakeyama H, Howard JD, Perez J, Considine M, Thakar M, Ranaweera R, Krigsfeld G, Chung CH. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma. Cancer Biol Ther. 2016 May.16(8):1252-1258. Pubmedid: 26046389. Pmcid: PMC4623002.
  • Khan Z, Epstein JB, Marur S, Boyd Gillespie M, Feldman L, Tsai HL, Zhang Z, Wang H, Sciubba J, Ferris RL, Grandis JR, Gibson M, Koch W, Tufano R, Westra W, Tsottles N, Ozawa H, Chung CH, Califano JA. Corrigendum to "Cetuximab activity in dysplastic lesions of the upper aerodigestive tract" [Oral Oncol. 53 (2016) 60-66]. Oral Oncol. 2016 Jun.57:e8. Pubmedid: 27085635. Pmcid: PMC7756201.
  • Han DK, Faries PL, Chung C, Weaver MV, Tadros RO, Ting W, Vouyouka AG. Intermediate Outcomes of Femoropopliteal Stenting in Women: 3-Year Results of the DURABILITY II Trial. Ann Vasc Surg. 2016 Jan.30:110-117. Pubmedid: 26585648.
  • Khan Z, Epstein JB, Marur S, Gillespie MB, Feldman L, Tsai HL, Zhang Z, Wang H, Sciubba J, Ferris R, Grandis JR, Gibson M, Koch W, Tufano R, Westra W, Tsottles N, Ozawa H, Chung C, Califano JA. Cetuximab activity in dysplastic lesions of the upper aerodigestive tract. Oral Oncol. 2016 Feb.53:60-66. Pubmedid: 26686755. Pmcid: PMC7751887.
  • Chung CH, Rudek MA, Kang H, Marur S, John P, Tsottles N, Bonerigo S, Veasey A, Kiess A, Quon H, Cmelak A, Murphy BA, Gilbert J. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Oral Oncol. 2016 Feb.53:54-59. Pubmedid: 26705063. Pmcid: PMC4707116.
  • Fakhry C, Qualliotine J, Zhang Z, Agrawal N, Gaykalova DA, Bishop JA, Subramanian RM, Koch WM, Chung CH, Eisele DW, Califano J, Viscidi RP. Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer. Cancer Prev Res (Phila). 2016 Feb.9(2):135-141. Pubmedid: 26701665. Pmcid: PMC4811031.
  • Zumsteg Z, Morse N, Krigsfeld G, Gupta G, Higginson D, Lee NY, Morris L, Ganly I, Shiao SL, Powell SN, Chung CH, Scaltriti M, Baselga J. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations. Clin Cancer Res. 2016 Apr.22(8):2009-2019. Pubmedid: 26589432. Pmcid: PMC4870591.
  • Yang W, McNutt TR, Dudley SA, Kumar R, Starmer HM, Gourin CG, Moore JA, Evans K, Allen M, Agrawal N, Richmon JD, Chung CH, Quon H. Predictive Factors for Prophylactic Percutaneous Endoscopic Gastrostomy (PEG) Tube Placement and Use in Head and Neck Patients Following Intensity-Modulated Radiation Therapy (IMRT) Treatment: Concordance, Discrepancies, and the Role of Gabapentin. Dysphagia. 2016 Apr.31(2):206-213. Pubmedid: 26753929.
  • Pathria MN, Chung CB, Resnick DL. Acute and Stress-related Injuries of Bone and Cartilage: Pertinent Anatomy, Basic Biomechanics, and Imaging Perspective. Radiology. 2016 07.280(1):21-38. Pubmedid: 27322971. Pmcid: PMC4942997.
  • Kim ES, Bernstein D, Hilsenbeck SG, Chung CH, Dicker AP, Ersek JL, Stein S, Khuri FR, Burgess E, Hunt K, Ivy P, Bruinooge SS, Meropol N, Schilsky RL. Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep.33(25):2815-2820. Pubmedid: 26195710.
  • Sheikhbahaei S, Taghipour M, Ahmad R, Fakhry C, Kiess AP, Chung CH, Subramaniam RM. Diagnostic Accuracy of Follow-Up FDG PET or PET/CT in Patients With Head and Neck Cancer After Definitive Treatment: A Systematic Review and Meta-Analysis. Ajr Am J Roentgenol. 2015 Sep.205(3):629-639. Pubmedid: 26295652.
  • Rettig EM, Chung CH, Fakhry C. Implications of the New Face of Head and Neck Cancer. Oncology (Williston Park). 2015 Sep.29(9):628-630. Pubmedid: 26384797.
  • Rettig EM, Wentz A, Posner MR, Gross ND, Haddad RI, Gillison ML, Fakhry C, Quon H, Sikora AG, Stott WJ, Lorch JH, Gourin CG, Guo Y, Xiao W, Miles BA, Richmon JD, Andersen PE, Misiukiewicz KJ, Chung CH, Gerber JE, Rajan SD, D'Souza G. Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. JAMA Oncol. 2015 Oct.1(7):907-915. Pubmedid: 26226294. Pmcid: PMC7286348.
  • Li R, Faden DL, Fakhry C, Langelier C, Jiao Y, Wang Y, Wilkerson MD, Pedamallu CS, Old M, Lang J, Loyo M, Ahn SM, Tan M, Gooi Z, Chan J, Richmon J, Wood LD, Hruban RH, Bishop J, Westra WH, Chung CH, Califano J, Gourin CG, Bettegowda C, Meyerson M, Papadopoulos N, Kinzler KW, Vogelstein B, DeRisi JL, Koch WM, Agrawal N. Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Head Neck. 2015 Nov.37(11):1642-1649. Pubmedid: 24954188. Pmcid: PMC4272912.
  • Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, Forastiere AA, Koch WM, Chung CH, Karchin R. Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Hum Genet. 2015 May.134(5):497-507. Pubmedid: 25108461. Pmcid: PMC4324386.
  • Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, James N, Rettig EM, Guo T, Pickering CR, Bishop JA, Chung CH, Califano JA, Eisele DW, Fakhry C, Gourin CG, Ha PK, Kang H, Kiess A, Koch WM, Myers JN, Quon H, Richmon JD, Sidransky D, Tufano RP, Westra WH, Bettegowda C, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Agrawal N. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015 Jun.7(293):293ra104. Pubmedid: 26109104. Pmcid: PMC4587492.
  • Guo T, Qualliotine JR, Ha PK, Califano JA, Kim Y, Saunders JR, Blanco RG, D'Souza G, Zhang Z, Chung CH, Kiess A, Gourin CG, Koch W, Richmon JD, Agrawal N, Eisele DW, Fakhry C. Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer. Cancer. 2015 Jun.121(12):1977-1984. Pubmedid: 25782027. Pmcid: PMC4457566.
  • Chung CH, Guthrie VB, Masica DL, Tokheim C, Kang H, Richmon J, Agrawal N, Fakhry C, Quon H, Subramaniam RM, Zuo Z, Seiwert T, Chalmers ZR, Frampton GM, Ali SM, Yelensky R, Stephens PJ, Miller VA, Karchin R, Bishop JA. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol. 2015 Jun.26(6):1216-1223. Pubmedid: 25712460. Pmcid: PMC4516044.
  • Maier S, Chung CH, Morse M, Platts-Mills T, Townes L, Mukhopadhyay P, Bhagavatheeswaran P, Racenberg J, Trifan OC. A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. Cancer Med. 2015 Jan.4(1):36-42. Pubmedid: 25296628. Pmcid: PMC4312116.
  • Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2015 Apr.51(4):376-382. Pubmedid: 25593015. Pmcid: PMC4459134.
  • Chang EY, Du J, Chung CB. UTE imaging in the musculoskeletal system. J Magn Reson Imaging. 2015 Apr.41(4):870-883. Pubmedid: 25045018. Pmcid: PMC4297256.
  • Parker HS, Leek JT, Favorov AV, Considine M, Xia X, Chavan S, Chung CH, Fertig EJ. Preserving biological heterogeneity with a permuted surrogate variable analysis for genomics batch correction. Bioinformatics. 2014 Oct.30(19):2757-2763. Pubmedid: 24907368. Pmcid: PMC4173013.
  • Zhang K, Jones L, Lim S, Maher CA, Adkins D, Lewis J, Kimple RJ, Fertig EJ, Chung CH, Van Tine BA, Ellis MJ, Herrlich A, Michel LS. Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC. Oncotarget. 2014 Oct.5(19):9281-9294. Pubmedid: 25238142. Pmcid: PMC4253434.
  • Alluri KC, Tahari AK, Wahl RL, Koch W, Chung CH, Subramaniam RM. Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma. Ajr Am J Roentgenol. 2014 Oct.203(4):897-903. Pubmedid: 25247958. Pmcid: PMC4332840.
  • Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2014 Nov.25(11):2230-2236. Pubmedid: 25081901. Pmcid: PMC4207729.
  • Pekala KR, Ma X, Kropp PA, Petersen CP, Hudgens CW, Chung CH, Shi C, Merchant NB, Maitra A, Means AL, Gannon MA. Loss of HNF6 expression correlates with human pancreatic cancer progression. Lab Invest. 2014 May.94(5):517-527. Pubmedid: 24638272. Pmcid: PMC4068339.
  • Yeh JC, Cheng MJ, Chung CH, Smith TJ. Using a question prompt list as a communication aid in advanced cancer care. J Oncol Pract. 2014 May.10(3):e137-e141. Pubmedid: 24594680. Pmcid: PMC4888050.
  • Sun M, Gomes S, Chen P, Frankenberger CA, Sankarasharma D, Chung CH, Chada KK, Rosner MR. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2. Oncogene. 2014 Jul.33(27):3528-3537. Pubmedid: 23975428. Pmcid: PMC4096871.
  • Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Carbone DP, Karrison TG, Vokes EE. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan.14:5. Pubmedid: 24386952. Pmcid: PMC3893521.
  • Sun W, Gaykalova DA, Ochs MF, Mambo E, Arnaoutakis D, Liu Y, Loyo M, Agrawal N, Howard J, Li R, Ahn S, Fertig E, Sidransky D, Houghton J, Buddavarapu K, Sanford T, Choudhary A, Darden W, Adai A, Latham G, Bishop J, Sharma R, Westra WH, Hennessey P, Chung CH, Califano JA. Activation of the NOTCH pathway in head and neck cancer. Cancer Res. 2014 Feb.74(4):1091-1104. Pubmedid: 24351288. Pmcid: PMC3944644.
  • Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan RC, Le QT. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol. 2014 Dec.32(35):3930-3938. Pubmedid: 25267748. Pmcid: PMC4251957.
  • Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014 Dec.32(34):3858-3866. Pubmedid: 25366680. Pmcid: PMC4239304.
  • Paidpally V, Chirindel A, Chung CH, Richmon J, Koch W, Quon H, Subramaniam RM. FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma. Ajr Am J Roentgenol. 2014 Aug.203(2):W139-W145. Pubmedid: 25055289. Pmcid: PMC4332824.
  • Howard JD, Moriarty WF, Park J, Riedy K, Panova IP, Chung CH, Suh KY, Levchenko A, Alani RM. Notch signaling mediates melanoma-endothelial cell communication and melanoma cell migration. Pigment Cell Melanoma Res. 2013 Sep.26(5):697-707. Pubmedid: 23773728.
  • Gajula RP, Chettiar ST, Williams RD, Thiyagarajan S, Kato Y, Aziz K, Wang R, Gandhi N, Wild AT, Vesuna F, Ma J, Salih T, Cades J, Fertig E, Biswal S, Burns TF, Chung CH, Rudin CM, Herman JM, Hales RK, Raman V, An SS, Tran PT. The twist box domain is required for Twist1-induced prostate cancer metastasis. Mol Cancer Res. 2013 Nov.11(11):1387-1400. Pubmedid: 23982216. Pmcid: PMC3833995.
  • Bauman JE, Arias-Pulido H, Lee SJ, Fekrazad MH, Ozawa H, Fertig E, Howard J, Bishop J, Wang H, Olson GT, Spafford MJ, Jones DV, Chung CH. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol. 2013 May.49(5):461-467. Pubmedid: 23384718. Pmcid: PMC3805493.
  • Lucs AV, Saltman B, Chung CH, Steinberg BM, Schwartz DL. Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. Head Neck. 2013 Feb.35(2):294-306. Pubmedid: 22287320. Pmcid: PMC4451948.
  • Slebos RJ, Jehmlich N, Brown B, Yin Z, Chung CH, Yarbrough WG, Liebler DC. Proteomic analysis of oropharyngeal carcinomas reveals novel HPV-associated biological pathways. Int J Cancer. 2013 Feb.132(3):568-579. Pubmedid: 22733545. Pmcid: PMC3479311.
  • Fertig EJ, Markovic A, Danilova LV, Gaykalova DA, Cope L, Chung CH, Ochs MF, Califano JA. Preferential activation of the hedgehog pathway by epigenetic modulations in HPV negative HNSCC identified with meta-pathway analysis. PLoS One. 2013.8(11):e78127. Pubmedid: 24223768. Pmcid: PMC3817178.
  • Chan JY, Sanguineti G, Richmon JD, Marur S, Gourin CG, Koch W, Chung CH, Quon H, Bishop JA, Aygun N, Agrawal N. Retrospective review of positron emission tomography with contrast-enhanced computed tomography in the posttreatment setting in human papillomavirus-associated oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2012 Nov.138(11):1040-1046. Pubmedid: 23165378. Pmcid: PMC3715070.
  • Bedi A, Chang X, Noonan K, Pham V, Bedi R, Fertig EJ, Considine M, Califano JA, Borrello I, Chung CH, Sidransky D, Ravi R. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Mol Cancer Ther. 2012 Nov.11(11):2429-2439. Pubmedid: 22927667. Pmcid: PMC3640459.
  • Fertig EJ, Ren Q, Cheng H, Hatakeyama H, Dicker AP, Rodeck U, Considine M, Ochs MF, Chung CH. Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma. BMC Genomics. 2012 May.13:160. Pubmedid: 22549044. Pmcid: PMC3460736.
  • Gillison ML, Zhang Q, Jordan R, Xiao W, Westra WH, Trotti A, Spencer S, Harris J, Chung CH, Ang KK. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol. 2012 Jun.30(17):2102-2111. Pubmedid: 22565003. Pmcid: PMC3397696.
  • Baumann JL, Li M, Poulsen A, Chadwick NS, Cai Q, Chung CH, Shyr Y, Olsen JH, Zheng W, Slebos RJ. Analysis of microsatellite mutations in buccal cells from a case-control study for lung cancer. Cancer Epidemiol. 2012 Feb.36(1):e33-e39. Pubmedid: 22056752. Pmcid: PMC3259162.
  • Gilbert J, Murphy B, Dietrich MS, Henry E, Jordan R, Counsell A, Wirth P, Yarbrough WG, Slebos RJ, Chung CH. Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer. Cancer. 2012 Feb.118(4):1007-1013. Pubmedid: 21766301.
  • Husain H, Psyrri A, Markovic A, Rampias T, Pectasides E, Wang H, Slebos R, Yarbrough WG, Burtness B, Chung CH. Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. Laryngoscope. 2012 Dec.122(12):2762-2768. Pubmedid: 23086695. Pmcid: PMC3574977.
  • Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012 Apr.18(7):2056-2065. Pubmedid: 22241789. Pmcid: PMC5157199.
  • Chung CH, Zhang Q, Hammond EM, Trotti AM, Wang H, Spencer S, Zhang HZ, Cooper J, Jordan R, Rotman MH, Ang KK. Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2011 Oct.81(2):331-338. Pubmedid: 20732768. Pmcid: PMC2992592.
  • Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL, Iafrate AJ, Pao W. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn. 2011 Jan.13(1):74-84. Pubmedid: 21227397. Pmcid: PMC3070558.
  • Ray KC, Bell KM, Yan J, Gu G, Chung CH, Washington MK, Means AL. Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. PLoS One. 2011 Feb.6(2):e16786. Pubmedid: 21311774. Pmcid: PMC3032792.
  • Chung CH, Pohlmann PR, Rothenberg ML, Burkey BB, Parker J, Palka K, Aulino J, Puzanov I, Murphy B. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head Neck. 2011 Dec.33(12):1804-1808. Pubmedid: 20652976. Pmcid: PMC3111896.
  • Chan E, Lafleur B, Rothenberg ML, Merchant N, Lockhart AC, Trivedi B, Chung CH, Coffey RJ, Berlin JD. Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Am J Clin Oncol. 2011 Dec.34(6):581-586. Pubmedid: 21217396. Pmcid: PMC3133812.
  • Wang J, Zhang K, Grabowska D, Li A, Dong Y, Day R, Humphrey P, Lewis J, Kladney RD, Arbeit JM, Weber JD, Chung CH, Michel LS. Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. Mol Cancer Res. 2011 Dec.9(12):1686-1695. Pubmedid: 21970857. Pmcid: PMC3243826.
  • Chung CH, Dignam JJ, Hammond ME, Klimowicz AC, Petrillo SK, Magliocco A, Jordan R, Trotti A, Spencer S, Cooper JS, Le QT, Ang KK. Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol. 2011 Apr.29(10):1326-1334. Pubmedid: 21357786. Pmcid: PMC3084000.
  • Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, Shyr Y, Slebos RJ, Chung CH. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One. 2010 Sep.5(9):e12702. Pubmedid: 20856931. Pmcid: PMC2938338.
  • Diaz R, Jaboin JJ, Morales-Paliza M, Koehler E, Phillips JG, Stinson S, Gilbert J, Chung CH, Murphy BA, Yarbrough WG, Murphy PB, Shyr Y, Cmelak AJ. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010 Jun.77(2):468-476. Pubmedid: 19577867.
  • Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul.363(1):24-35. Pubmedid: 20530316. Pmcid: PMC2943767.
  • Murphy BA, Dietrich MS, Wells N, Dwyer K, Ridner SH, Silver HJ, Gilbert J, Chung CH, Cmelak A, Burkey B, Yarbrough WG, Sinard R, Netterville J. Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation. Head Neck. 2010 Jan.32(1):26-37. Pubmedid: 19626644.
  • Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev. 2010 Feb.19(2):358-365. Pubmedid: 20086114. Pmcid: PMC2846615.
  • Li M, Gray W, Zhang H, Chung CH, Billheimer D, Yarbrough WG, Liebler DC, Shyr Y, Slebos RJ. Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling. J Proteome Res. 2010 Aug.9(8):4295-4305. Pubmedid: 20586475. Pmcid: PMC2920032.
  • Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, Netterville J, Sinard R, Yarbrough WG, Cmelak AJ, Slebos RJ, Shyr Y, Parker J, Gilbert J, Murphy BA. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2010 Apr.21(4):864-870. Pubmedid: 19850643. Pmcid: PMC2844946.
  • Le QT, Harris J, Magliocco AM, Kong CS, Diaz R, Shin B, Cao H, Trotti A, Erler JT, Chung CH, Dicker A, Pajak TF, Giaccia AJ, Ang KK. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol. 2009 Sep.27(26):4281-4286. Pubmedid: 19667273. Pmcid: PMC2744270.
  • Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y, Moses HL. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest. 2009 Jun.119(6):1571-1582. Pubmedid: 19451693. Pmcid: PMC2689133.
  • Cohen EE, Zhu H, Lingen MW, Martin LE, Kuo WL, Choi EA, Kocherginsky M, Parker JS, Chung CH, Rosner MR. A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res. 2009 Jan.69(1):65-74. Pubmedid: 19117988. Pmcid: PMC2746005.
  • Baumann JL, Cohen S, Evjen AN, Law JH, Vadivelu S, Attia A, Schindler JS, Chung CH, Wirth PS, Meijer CJ, Snijders PJ, Yarbrough WG, Slebos RJ. Human papillomavirus in early laryngeal carcinoma. Laryngoscope. 2009 Aug.119(8):1531-1537. Pubmedid: 19489068.
  • Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, Arteaga CL. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol. 2008 Sep.28(18):5605-5620. Pubmedid: 18625725. Pmcid: PMC2546920.
  • Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008 Mar.358(11):1109-1117. Pubmedid: 18337601. Pmcid: PMC2361129.
  • Gilbert J, Cmelak A, Shyr Y, Netterville J, Burkey BB, Sinard RJ, Yarbrough WG, Chung CH, Aulino JM, Murphy BA. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. Cancer. 2008 Jul.113(1):186-192. Pubmedid: 18484593.
  • Slebos RJ, Li M, Vadivelu S, Burkey BB, Netterville JL, Sinard R, Gilbert J, Murphy B, Chung CH, Shyr Y, Yarbrough WG. Microsatellite mutations in buccal cells are associated with aging and head and neck carcinoma. Brit J Cancer. 2008 Feb.98(3):619-626. Pubmedid: 18212747. Pmcid: PMC2243146.
  • Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, Burkey BB, Sinard R, Cmelak A, Levy S, Yarbrough WG, Slebos RJ, Hirsch FR. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 2006 Sep.24(25):4170-4176. Pubmedid: 16943533.
  • Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, Zhang X, Shyr Y, Murphy BM, Cmelak AJ, Burkey BB, Netterville JL, Levy S, Yarbrough WG, Chung CH. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res. 2006 Feb.12(3 Pt 1):701-709. Pubmedid: 16467079.
  • Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, Ang KK, El-Naggar AK, Zanation AM, Cmelak AJ, Levy S, Slebos RJ, Yarbrough WG. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 2006 Aug.66(16):8210-8218. Pubmedid: 16912200.
  • Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X, Shockley WW, Weissler MC, Dressler LG, Shores CG, Yarbrough WG, Perou CM. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004 May.5(5):489-500. Pubmedid: 15144956.
  • Rohlfs EM, Chung CH, Yang Q, Skrzynia C, Grody WW, Graham ML, Silverman LM. In-frame deletions of BRCA1 may define critical functional domains. Hum Genet. 2000 Oct.107(4):385-390. Pubmedid: 11129340.
  • Wilentz RE, Chung CH, Sturm PD, Musler A, Sohn TA, Offerhaus GJ, Yeo CJ, Hruban RH, Slebos RJ. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer. 1998 Jan.82(1):96-103. Pubmedid: 9428484.
  • Chung CH, Wilentz RE, Polak MM, Ramsoekh TB, Noorduyn LA, Gouma DJ, Huibregtse K, Offerhaus GJ, Slebos RJ. Clinical significance of K-ras oncogene activation in ampullary neoplasms. J Clin Pathol. 1996 Jun.49(6):460-464. Pubmedid: 8763258. Pmcid: PMC500534.

Grants

Title: Evaluation of MHC class I methylation as a mechanism of checkpoint inhibitor resistance in head and neck squamous cell carcinoma (HNSCC)
Sponsor: Bristol Myers Squibb Company
PI: Chung, C.
Title: PI3K Pathway Activation and Its Associated Genomic Profile as Predictive Biomarkers of HPV-Related Oropharyngeal Cancer
Sponsor: Nat Institutes of Health
PI: Chung, C.
Title: Decoding Tobacco-related Oral Cancer Ecosystem by Integrative Approach
Sponsor: Nat Institutes of Health
PI: Chung, C.
Title: M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention
Sponsor: Nat Institutes of Health
PI: Chung, C.
Title: Effects of hypoxia in tumor immune microenvironment in tobacco-related head and neck squamous cell carcinoma (HNSCC)
Sponsor: Florida Biomedical Research Program (FBRP)
PI: Chung, C., CO-PI: Song, X.

Patient Comments
Overall Satisfaction
4.8
★★★★★
★★★★★

58 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments